Commercialization: Page 5
-
3 ways pharma can prep for Biden’s sweeping drug pricing policies
Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.
By Karissa Waddick • Aug. 18, 2022 -
Podcast
Woman of the Week: Takeda Oncology’s Teresa Bitetti
Upon joining Takeda Pharmaceuticals as president of the global oncology unit, Teresa Bitetti had two important goals: to transform the business and create greater synergies between commercial and R&D operations.
By Taren Grom • Aug. 17, 2022 -
The FDA is mulling an OTC approval for a birth control. Will politics factor in?
Analysts are watching how cultural and political debates around reproductive rights may impact HRA Pharma's OTC birth control application.
By Karissa Waddick • Aug. 15, 2022 -
Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics
Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.
By Michael Gibney • Aug. 11, 2022 -
4 ways to nail the launch of your cell therapy
A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.
By Meagan Parrish • Aug. 10, 2022 -
Making Moves
Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires
How these latest executive personnel changes are impacting the industry.
By Karissa Waddick • Aug. 3, 2022 -
Q&A
A glimpse inside Bristol Myers Squibb’s integration with Celgene
Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.
By Meagan Parrish • Aug. 1, 2022 -
Pfizer's former R&D head takes on drug pricing misconceptions in new book
John LaMattina has something to say about the industry — and he hopes patients are listening.
By Meagan Parrish • July 19, 2022 -
Making Moves
Making moves: Agios, BeiGene, Biocom California and more announce new key hires
The latest executive personnel changes from around the industry.
By Karissa Waddick • July 18, 2022 -
Q&A // First 90 Days
Anjarium Biosciences’ CEO on its next-gen gene therapies
Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.
By Kim Ribbink • July 15, 2022 -
Q&A
Janssen extends LGBTQ mental health outreach beyond Pride Month
The pharma giant’s ‘Depression looks like me’ campaign assembles a ‘one stop shop’ of resources to help combat high rates of severe depression in the LGBTQ community.
By Karissa Waddick • July 14, 2022 -
Podcast
Woman of the Week: Kura Oncology's Kirsten Flowers
How the chief commercial and corporate strategy officer is embracing a ‘full-cup’ philosophy to build a better leadership toolbox.
By Taren Grom • July 13, 2022 -
Q&A
COVID won't evolve to become 'less deadly' — and RedHill is prepping for the long haul
RedHill Biopharma’s chief operating officer, Guy Goldberg, says the company’s oral COVID-19 therapy could still be needed on a global scale.
By Kim Ribbink • July 12, 2022 -
Behind the new topical treatment set to disrupt the psoriasis market
Phil Brown, Dermavant’s chief medical officer, discusses VTAMA — the first topical cream approved for psoriasis in 25 years.
By Kelly Bilodeau • July 11, 2022 -
Q&A
The CEO of Dr. Reddy's N. America is using 'controlled explosions' to keep the generics giant growing
Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.
By Meagan Parrish • July 7, 2022 -
Podcast
Woman of the Week: CinCor Pharma's Terry Coelho
From M&Ms to biotech, the chief financial officer's sweet tooth for taking risks is paying off.
By Taren Grom • July 6, 2022 -
Pharma companies take a fresh approach to inclusion in new DTC ads
AstraZeneca and Amgen are emphasizing diversity and authenticity in campaigns for lupus and severe asthma therapies.
By Karissa Waddick • July 5, 2022 -
Podcast
Woman of the Week: Novartis' Marie-France Tschudin
How the chief commercial officer and president of innovative medicines international plans to fuel growth and productivity at the company.
By Taren Grom • June 29, 2022 -
With abortion access restricted across the U.S., a new diagnostic aims to eliminate birth control's pain points
The hormonal and genetic test developed by Adyn is designed to predict and prevent adverse birth control side effects.
By Karissa Waddick • June 28, 2022 -
A myriad of blows: Who's getting hit the hardest by the economy's troubles
The downturn shows few signs of hurting large pharma, but small biotechs and generics makers could face a credit crunch.
By Kim Ribbink • June 27, 2022 -
TikTok tutorial: How pharma can embrace the video platform's educational potential
Ogilvy Health’s director of social strategy, Katie Ferrigno, busts myths and provides tips on how biopharmas can take advantage of TikTok’s unique features to connect with patients.
By Karissa Waddick • June 15, 2022 -
Aduhelm's Medicare woes leave questions about lofty premiums
A single drug’s effect on the premiums that Medicare beneficiaries pay is raising questions about how these levels are set and what factors play a part.
By Kelly Bilodeau • June 2, 2022 -
Profile
Flagship's creative approach to finding the next big idea in biopharma
Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.
By Alexandra Pecci • June 1, 2022 -
PBMs under fire for drug prices defend their worth
A new Senate bill is putting PBMs in the crosshairs of lawmakers — but they argue that they're more than just middlemen.
By Michael Gibney • May 26, 2022 -
Q&A
Ironwood Pharmaceuticals is charting a course to become a giant in GI
Ironwood’s CEO, Tom McCourt, discusses the company’s strategy for leveling up in the GI market.
By Karissa Waddick • May 19, 2022